Blood Safety

Phase II Results Show Inactine Effectively Treats Red Blood Cells

Published in Hepatitis Weekly, January 7th, 2002

V.I. Technologies, Inc., (Vitex) announced results of a Phase II study of its Inactine Pathogen Inactivation System for red cells at the December 2001 American Society of Hematology meeting.

The results demonstrated for the first time that full units of Inactine-treated red cells could be safely reinfused into healthy volunteers after 42 days of storage.

The Phase II study included 48 healthy adult volunteers and evaluated the safety and maximum storage time of a full unit of red blood cells treated with Inactine for 24 hours versus untreated red blood cells. The Inactine-treated red blood cells met the regulatory requirement for greater than 75%...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-01-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry